Bruce Seeley has joined CTI BioPharma, a US developer of drugs for blood-related cancers, as Executive Vice President and Chief Commercial Officer, reporting to President and CEO James Bianco.
Seeley has taken responsibility for the Seattle, WA-based company's commercial organisation worldwide – including sales, marketing, commercial operations, medical affairs and supply chain.
He has more than 25 years of global commercial experience and a proven track record of successfully launching products in various markets and regulatory environments.
Most recently he was Senior Vice President and General Manager of Diagnostics at NanoString Technologies. Before this he was Executive Vice President of Commercial at Seattle Genetics.
He also previously held key leadership positions in marketing at Genentech and Aventis Pharmaceuticals, and in sales at Bristol-Myers Squibb.
In connection with the transition of medical affairs to the new Chief Commercial Officer, Dr Jack Singer has moved to the position of Chief Scientific Officer and will continue to serve as Executive Vice President, Interim Chief Medical Officer and Global Head of Translational Medicine.
